Lepu Biotech-B (02157.HK) has signed a CDMO service framework agreement with lepu medical technology.

On November 26, Gleam Hill reported that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, pursuant to which the company and/or its subsidiaries agreed to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.

Gelonghui FinanceNov 26 08:44 ET

Luoping Biotechnology -B (02157.HK) intends to appoint Ernst & Young as the new auditor.

Gelonghui, November 26 - Lepu Bio-B (02157.HK) announced that PricewaterhouseCoopers has agreed to resign as the company's auditor, effective November 26, 2024. The company intends to appoint Ernst & Young as the new auditor for the 2024 fiscal year, with the term ending at the conclusion of the company's next annual general meeting of shareholders.

Gelonghui FinanceNov 26 08:23 ET

Hong Kong stock market anomaly | Some pharmaceutical stocks rise, medical insurance negotiations support innovative drugs. Institutions point out that the sector still has further room for recovery.

Some pharmaceutical stocks rose, as of the deadline, SciClone Pharmaceuticals-B (02171) rose by 33.68% to HK$8.97; Concord Jingrui Pharmaceuticals-B (09966) rose by 10.34% to HK$4.27; LuPu Biotech-B (02157) rose by 7.87% to HK$3.29.

Zhitong FinanceNov 7 21:48 ET

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Simply Wall StOct 12 22:23 ET

Lepu Biopharma Cancer Drug's NDA Approved by China's NDMA; Stocks Up 8%

MT NewswiresSep 26 23:39 ET

Luoping Biosciences-B (02157.HK): MRG003 for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) has been accepted for new drug application by the National Medical Products Administration and included in priority review.

September 27, Geelonghui - The company LePu Biology-B (02157.HK) announced that it has received the "Acceptance Notice" issued by the China National Medical Products Administration (NMPA). The company's candidate drug MRG003 (an epidermal growth factor receptor (EGFR) targeted antibody-drug conjugate (ADC) candidate drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC))'s new drug application (NDA) has been accepted. MRG003 has also been included in the priority review by the NMPA Center for Drug Evaluation (CDE) ("Priority Review").

Gelonghui FinanceSep 26 20:08 ET